INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
89 hedge funds and large institutions have $286M invested in Inozyme Pharma in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 90 → 89 (-1)
39% less call options, than puts
Call options by funds: $22K | Put options by funds: $36K
Holders
89
Holding in Top 10
1
Calls
$22K
Puts
$36K
Top Buyers
| 1 | +$1.2M | |
| 2 | +$1.04M | |
| 3 | +$783K | |
| 4 |
BlackRock
New York
|
+$774K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$547K |
Top Sellers
| 1 | -$1.42M | |
| 2 | -$564K | |
| 3 | -$478K | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$289K |
| 5 |
Millennium Management
New York
|
-$227K |